- Home
- MIST vs RLAY Comparison
MIST vs RLAY Comparison
Compare MIST & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MIST | RLAY |
|---|---|---|
| Founded | 2003 | 2015 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 176.3M | 2.5B |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MIST | RLAY |
|---|---|---|
| Price | $1.50 | $12.27 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | $8.00 | ★ $19.50 |
| AVG Volume (30 Days) | 1.4M | ★ 2.8M |
| Earning Date | 05-13-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.78 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $15,355,000.00 |
| Revenue This Year | $2,915.14 | N/A |
| Revenue Next Year | N/A | $324.03 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 53.44 |
| 52 Week Low | $1.00 | $2.75 |
| 52 Week High | $3.06 | $17.32 |
Technical Indicators
Market Signals| Indicator | MIST | RLAY |
|---|---|---|
| Relative Strength Index (RSI) | 33.77 | 41.49 |
| Support Level | $1.40 | $11.75 |
| Resistance Level | $2.01 | $17.32 |
| Average True Range (ATR) | 0.12 | 0.83 |
| MACD | -0.05 | -0.23 |
| Stochastic Oscillator | 6.36 | 15.66 |
Price Performance
Historical ComparisonAbout MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.